Summary
MAM-2201, also known as 4′-methyl-AM-2201 or 5″-fluoro-JWH-122 is believed to act as a potent agonist for cannabinoid receptors. This compound remained undocumented in scientific or patent literature until laboratories in the Netherlands and Germany first discovered it in June 2011 when used as an ingredient in synthetic cannabis smoking blends. Like RCS-4 and AB-001, MAM-2201 appears to be a novel creation by “research chemical” suppliers, primarily intended for recreational use in the grey market. Structurally, MAM-2201 is a hybrid combining elements from two well-known cannabinoid compounds, JWH-122 and AM-2201, both of which were previously employed as active ingredients in synthetic cannabis blends before being prohibited in numerous countries.
An investigation of MAM-2201 conducted on rats indicated that it induces neurofunctional disruptions. Subsequently, another study demonstrated that MAM-2201 binds to and activates human CB1 and CB2 cannabinoid receptors, and it can substitute for THC in THC drug discrimination tests conducted on mice.
| Identifiers | |
|---|---|
| IUPAC name | |
| CAS Number | 1354631-24-5 |
|---|---|
| PubChem CID | 66570720 |
| ChemSpider | 28289977 |
| UNII | P4KP9PRG29 |
| CompTox Dashboard (EPA) | DTXSID20159387 |
| ECHA InfoCard | 100.257.545 |
| Chemical and physical data | |
| Formula | C25H24FNO |
| Molar mass | 373.471 g·mol−1 |
Legal status
In the United States, all CB1 receptor agonists belonging to the 3-(1-naphthyl)indole class, including MAM-2201, are categorized as Schedule I Controlled Substances.
New Zealand banned MAM-2201 by including it in the temporary class drug schedule, effective 13 July 2012.
Furthermore, as of October 2015, MAM-2201 is classified as a controlled substance in China.
FAQ
1. What is MAM-2201?
MAM-2201 is a synthetic cannabinoid compound known for its potential to act as a potent agonist for cannabinoid receptors, primarily the CB1 receptor.
2. How was MAM-2201 discovered?
MAM-2201 had not been reported in scientific or patent literature until laboratories in the Netherlands and Germany identified it in June 2011. It was initially used as an ingredient in synthetic cannabis smoking blends.
3. What is the structural composition of MAM-2201?
Structurally, MAM-2201 is a hybrid compound, incorporating elements from two known cannabinoid compounds, JWH-122 and AM-2201.
4. Is MAM-2201 legal in the United States?
No, in the United States, MAM-2201, like other CB1 receptor agonists of the 3-(1-naphthyl)indole class, is classified as a Schedule I Controlled Substance.
5. Has MAM-2201 been banned in other countries?
Yes, New Zealand added MAM-2201 to its temporary class drug schedule, effectively banning it from 13 July 2012. Additionally, as of October 2015, China has categorized MAM-2201 as a controlled substance.
6. What are the pharmacological effects of MAM-2201?
MAM-2201 has been shown to induce neurofunctional disruptions in rats. It also binds to and activates human CB1 and CB2 cannabinoid receptors and can substitute for THC in drug discrimination tests conducted on mice.
7. What is the recreational use of MAM-2201?
MAM-2201 was initially created by “research chemical” suppliers for recreational use in the grey market, similar to other synthetic cannabinoids, such as RCS-4 and AB-001.
8. Is MAM-2201 safe for use?
The safety of MAM-2201 has not been extensively studied, and its use can have unpredictable and potentially harmful effects. It is essential to prioritize safety and adhere to legal regulations regarding its use.
References
- Brazil’s Regulatory Measures: In Brazil, MAM-2201 falls under strict regulations, listed as a controlled substance according to RDC Nº 804. These measures aim to control the distribution and use of such substances to ensure public safety.
- Analyzing Metabolites: Research has been dedicated to understanding MAM-2201’s effects on the body. Studies have identified metabolites of MAM-2201 in postmortem plasma and urine, shedding light on its pharmacokinetics and potential health implications.
- Metabolome Disruption: Investigation into MAM-2201’s impact on the cerebrum reveals significant metabolome disruption. The synthetic cannabinoid’s acute toxic effects have been studied to comprehend its potential risks.
- Continuing Characterization: Researchers are continuing to delve into the characterization of synthetic cannabinoids like MAM-2201. Understanding their properties and effects is essential to mitigate potential harm and enhance safety measures.
- Global Regulatory Responses: Various countries have responded to the emergence of substances like MAM-2201 by classifying them as controlled substances. China, New Zealand, and the United States have implemented measures to control the distribution and use of this synthetic cannabinoid.